Publicado em 30 jan 2023
FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if COVID-19 symptoms return
The FDA rebuked Pfizer CEO Albert Bourla’s proposed solution to reports that some patients experienced a relapse of COVID-19 symptoms after treatment with the company’s antiviral Paxlovid.
Leia matéria na íntegra em https://www.fiercepharma.com/pharma/fda-rebukes-pfizers-suggestion-take-more-paxlovid-if-covid-19-symptoms-return
